Cellectar Biosciences (CLRB)
NASDAQ:CLRB
Want to see CLRB full AI Analyst Report?
CLRB Stock Chart & Stats
$3.29
-$0.03(-9.33%)
At close: 4:00 PM EST
$3.29
-$0.03(-9.33%)
Day’s Range― - ―
52-Week Range$2.20 - $13.48
Previous CloseN/A
Volume1.30M
Average Volume (3M)105.19K
Market Cap
$17.98M
Enterprise Value$3.20M
Total Cash (Recent Filing)$8.35M
Total Debt (Recent Filing)$1.53M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Aug 19, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.38
Shares Outstanding7,991,812
10 Day Avg. Volume157,484
30 Day Avg. Volume105,193
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.78
Price to Sales (P/S)0.00
P/FCF Ratio-0.33
Enterprise Value/Market Cap0.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit29.13
Enterprise Value/Ebitda-0.15
Forecast
1Y Price Target
$10.33Price Target Upside214.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.13
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy & Regulatory PathRobust Phase IIb results with high ORR and durable responses materially improve the likelihood of regulatory acceptance for accelerated approval. Breakthrough designation supports expedited review and an earlier path to market, strengthening the long-term commercial potential in WM and reducing binary clinical risk.
Diversified Radiopharma PlatformAdvancing CLR125 into a TNBC Phase Ib study demonstrates platform applicability beyond hematologic disease, expanding addressable markets into solid tumors. A multi-asset PLE targeting approach lowers single-asset dependency, increases licensing/commercial optionality, and supports a durable R&D strategy if early signals are positive.
Financing And Institutional AlignmentA committed financing package substantially extends runway to support Phase III start and potential commercialization, reducing immediate liquidity pressure. Inclusion of institutional investors and a board representative enhances governance, fundraising credibility, and access to capital markets over the medium term.
Bears Say
Cash Burn & Negative Cash FlowSustained negative operating and free cash flow indicates the company is structurally cash consumptive and dependent on external financing. Even with improved burn versus 2024, continued deficits constrain strategic flexibility, heighten refinancing needs, and increase risk if clinical timelines or fundraising are delayed.
Contingent Financing RiskA large portion of committed capital is contingent on clinical, regulatory, and stock‑performance triggers. Failure to satisfy milestones or trading conditions could deny material funding, forcing dilutive financings or program delays, thereby making the company's execution and liquidity sensitive to both operational and market factors.
Pre-revenue Model & Execution DependenceAs a clinical‑stage, pre‑revenue biotech, long‑term viability hinges on successful trials, regulatory approval, or partnerships. Without product revenue, prolonged development timelines or negative trial outcomes would necessitate repeated external funding, increase dilution risk, and limit the company’s ability to build sustainable commercial operations.
Cellectar Biosciences News
CLRB FAQ
What was Cellectar Biosciences’s price range in the past 12 months?
Cellectar Biosciences lowest stock price was $2.20 and its highest was $13.48 in the past 12 months.
What is Cellectar Biosciences’s market cap?
Cellectar Biosciences’s market cap is $17.98M.
When is Cellectar Biosciences’s upcoming earnings report date?
Cellectar Biosciences’s upcoming earnings report date is Aug 19, 2026 which is in 66 days.
How were Cellectar Biosciences’s earnings last quarter?
Cellectar Biosciences released its earnings results on May 14, 2026. The company reported -$1.33 earnings per share for the quarter, beating the consensus estimate of -$1.885 by $0.555.
Is Cellectar Biosciences overvalued?
According to Wall Street analysts Cellectar Biosciences’s price is currently Undervalued.
Does Cellectar Biosciences pay dividends?
Cellectar Biosciences does not currently pay dividends.
What is Cellectar Biosciences’s EPS estimate?
Cellectar Biosciences’s EPS estimate is -0.48.
How many shares outstanding does Cellectar Biosciences have?
Cellectar Biosciences has 7,991,812 shares outstanding.
What happened to Cellectar Biosciences’s price movement after its last earnings report?
Cellectar Biosciences reported an EPS of -$1.33 in its last earnings report, beating expectations of -$1.885. Following the earnings report the stock price went up 8.844%.
Which hedge fund is a major shareholder of Cellectar Biosciences?
Currently, no hedge funds are holding shares in CLRB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cellectar Biosciences
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
CLRB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized major clinical progress for iopofosine (robust Phase IIb 12‑month data with high ORR, durable responses, and regulatory strategy toward accelerated approval) and an oversubscribed financing structure intended to fund late‑stage development. Operational progress on CLR125 and cost discipline were also highlighted. Key risks include a low pre‑financing cash balance, reliance on milestone‑contingent funding with market‑performance conditions, continued net losses, and tight timelines for Phase III initiation and regulatory milestones. On balance, the positive clinical data and financing momentum significantly outweigh the contingent funding and timing risks.View all CLRB earnings summariesCLRB Stock 12 Month Forecast
Average Price Target
$10.33
▲(214.08% Upside)
Technical Analysis
Ownership Overview
0.59% Insiders
1.45% Mutual Funds
1.56% Other Institutional Investors
95.38% Public Companies and
Individual Investors